To describe the clinical response to Eculizumab (ECU) and Efgartigimod (EFGA) in a real-life setting in patients with generalized Myasthenia Gravis (gMG).
No takes yet. Share an insight, caveat, or question.
Saccà et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: